Back to top
more

ETFMG Treatments, Testing and Advancements ETF: (GERM)

(Delayed Data from NYSE) As of Oct 18, 2021 03:57 PM ET

 Add to portfolio

$38.35 USD

38.35
15,778

-0.09 (-0.22%)

Volume: 15,778

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

After-Market: $38.37 +0.02 (0.05 %) 5:20 PM ET

ETF Quote Details

Previous Close 38.44
Open 38.13
Bid 38.02
Ask 38.68
Day Low-High 37.69-38.42
52wk Low-High 26.81-46.06
Volume 15,778
NAV (month end) 40.63
Premium (+)/Discount (-) (month end)-2.19

Zacks Premium Research for GERM

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 NA
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

NA
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.68%
Dividend (Yield) $0.38 (1.00%)
Issuer ETF MANAGERS

Benchmark for GERM

PRIME TREATMENTS TESTING & ADVNCMNTS ID

The Prime Treatments, Testing and Advancements Index provides investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

Fund Summary for GERM

ETFMG TREATMENTS TESTING & ADVNCMNTS ETF

The ETFMG Treatments, Testing and Advancements ETF provides investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.